Table 4 Virus circulation and treatment efficacy

From: Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors

   

Virus circulation

Response

Code

Dose a

it/iv/ic b

Days post treatment c

Weeks post treatment c

RECISd/

Tumor

Survival

 

(VP)

(% from dose)

0

1

2–4

6–10

2

3

4

5

density

markers

 

K2

2.6 × 109

50/50/0

0

0

<500

<500

0

     

55

S4

6 × 109

100/0/0

0

0

0

0

      

58

C6

6 × 109

100/0/0

0

0

 

1712

 

0

  

PD/Choi -16%

SD

57

H7

9 × 109

0/0/100

 

0

 

0

 

0

0

0

 

PR/PD

149

H5

1 × 1010

100/0/0

0

<500

15 104

  

<500

 

0

 

MR/SD

47

O9

2 × 1010

0/0/100

0

0

0

 

0

 

0

 

PD

PD

212

G11

2 × 1010

50/0/50

0

 

1701

947

   

3151

 

MR/SD

47

C13

5 × 1010

40/20/40

0

0

4774

<500

0

0

 

0

PD/Choi -9%

PR

105

R10

5.3 × 1010

75/25/0

 

<500

59 555

7899

6377

  

<500

 

MR

52

O16

1 × 1011

0/20/80

 

<500

       

PD

108

N21

1 × 1011

67/33/0

0

6540

   

<500

  

PR (−33%)

SD

489e

C17

1.2 × 1011

67/33/0

 

<500

<500

      

SD

152

P20

2 × 1011

33/67/0

0

<500

8626

 

<500

0

0

  

PD

127

H22

2 × 1011

0/33/67

0

0

<500

 

<500

0

 

0

 

PD

138

O24

2 × 1011

50/0/50

0

0

959

  

0

 

0

MR (−12%)

MR

147

O25

2 × 1011

50/0/50

0

0

<500

562

      

66–96f

P27

3 × 1011

70/10/20

0

<500

5 259 766

 

76603

 

1755

  

SD

44

O37

3 × 1011

40/40/20

0

<500

0

       

124

  1. Abbreviations: MR, minor response; PD, progressive disease; PR, partial response; SD, stable disease; VP, viral particles.
  2. aTotal dose of viral particles.
  3. bProportion of viral particles from total dose given intratumorally/intravenously/intracavitary.
  4. cValues are viral particles per ml serum.
  5. dResponse Evaluation Criteria In Solid Tumors.
  6. ePatient alive at the time of table construction.
  7. fExact date of death unknown. Blank indicates not available.
Back to article page